Outcomes After Recurrent Intentional Methanol Exposures Not Treated With Alcohol Dehydrogenase Inhibitors Or Hemodialysis.


Journal

The Journal of emergency medicine
ISSN: 0736-4679
Titre abrégé: J Emerg Med
Pays: United States
ID NLM: 8412174

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 08 11 2019
revised: 28 02 2020
accepted: 18 03 2020
pubmed: 21 4 2020
medline: 24 6 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Relying on a treatment threshold for methanol poisoning of 20 mg/dL (6.2 mmol/L) as a stand-alone criterion may lead to unnecessary and invasive treatment because it is likely too conservative, especially for patients with repeated, intentional methanol exposures. We investigated how often patients with recurrent intentional methanol exposures above this threshold developed biochemical or overt clinical toxicity despite not being treated with either an alcohol dehydrogenase inhibitor (ADHi) or hemodialysis. We identified patients with ≥3 methanol-related emergency visits from 2002 to 2015 and selected every visit in which neither ADHi nor hemodialysis were administered despite serum methanol >20 mg/dL but neither metabolic acidosis nor end organ toxicity at presentation. The primary outcome was the incidence of visual deterioration or death. Four patients accounted for the 17 visits that met inclusion criteria. All exposures were intentional substance misuse, and 7 of 17 were via inhalation (i.e., huffing). Initial methanol concentrations ranged from 22 mg/dL to 35 mg/dL (7-11 mmol/L). Four of these 17 visits had undetectable initial ethanol concentrations at presentation, including 1 with an initial methanol concentration of 35 mg/dL. No patients developed visual deterioration, and all were known to have survived the exposure. Following recurrent, intentional methanol exposure, isolated serum methanol concentrations as high as 35 mg/dL (11 mmol/L) appear to be well-tolerated without treatment in the absence of metabolic acidosis or end-organ toxicity. To better define the methanol treatment threshold, prospective studies are warranted in which patients are followed closely while fomepizole is withheld.

Sections du résumé

BACKGROUND BACKGROUND
Relying on a treatment threshold for methanol poisoning of 20 mg/dL (6.2 mmol/L) as a stand-alone criterion may lead to unnecessary and invasive treatment because it is likely too conservative, especially for patients with repeated, intentional methanol exposures.
OBJECTIVE OBJECTIVE
We investigated how often patients with recurrent intentional methanol exposures above this threshold developed biochemical or overt clinical toxicity despite not being treated with either an alcohol dehydrogenase inhibitor (ADHi) or hemodialysis.
METHODS METHODS
We identified patients with ≥3 methanol-related emergency visits from 2002 to 2015 and selected every visit in which neither ADHi nor hemodialysis were administered despite serum methanol >20 mg/dL but neither metabolic acidosis nor end organ toxicity at presentation. The primary outcome was the incidence of visual deterioration or death.
RESULTS RESULTS
Four patients accounted for the 17 visits that met inclusion criteria. All exposures were intentional substance misuse, and 7 of 17 were via inhalation (i.e., huffing). Initial methanol concentrations ranged from 22 mg/dL to 35 mg/dL (7-11 mmol/L). Four of these 17 visits had undetectable initial ethanol concentrations at presentation, including 1 with an initial methanol concentration of 35 mg/dL. No patients developed visual deterioration, and all were known to have survived the exposure.
CONCLUSION CONCLUSIONS
Following recurrent, intentional methanol exposure, isolated serum methanol concentrations as high as 35 mg/dL (11 mmol/L) appear to be well-tolerated without treatment in the absence of metabolic acidosis or end-organ toxicity. To better define the methanol treatment threshold, prospective studies are warranted in which patients are followed closely while fomepizole is withheld.

Identifiants

pubmed: 32307216
pii: S0736-4679(20)30160-8
doi: 10.1016/j.jemermed.2020.03.024
pii:
doi:

Substances chimiques

Antidotes 0
Pyrazoles 0
Alcohol Dehydrogenase EC 1.1.1.1
Methanol Y4S76JWI15

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

910-916

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Yang Steven Liu (YS)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada.

Katie Y Lin (KY)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada.

Joanne Masur (J)

Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta, Canada.

Shalyn Barby (S)

Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta, Canada.

Ryan Chuang (R)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada; Rocky Mountain Poison and Drug Safety, Denver Health, Denver, Colorado.

David W Johnson (DW)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada; Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta, Canada; Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Clinical Pharmacology and Toxicology, Alberta Health Services, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.

Scott N Lucyk (SN)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada; Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta, Canada; Section of Clinical Pharmacology and Toxicology, Alberta Health Services, Calgary, Alberta, Canada.

Marco L A Sivilotti (MLA)

Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada; Ontario Poison Centre, Toronto, Ontario, Canada.

Mark C Yarema (MC)

Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada; Poison and Drug Information Service, Alberta Health Services, Calgary, Alberta, Canada; Section of Clinical Pharmacology and Toxicology, Alberta Health Services, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH